Clinical Trial Update: Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update evaluating Olimersen in combination with Irinotecan for metastatic or recurrent colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• Olimersen (oblimersen)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Colorectal Cancer | Phase 1, Phase 2 | Status: COMPLETED